Breakthrough T1D – Artificial Intelligence Powered Approaches for T1D Cell Therapy
![Thumbnail](http://memento.epfl.ch/image/28425/1440x810.jpg)
Event details
Date | 23.09.2024 |
Category | Call for proposal |
Aim: RFA seeks to support research projects aiming to advance the development of next generation beta cell replacement therapies for type 1 diabetes by leveraging advancements in artificial intelligence (AI) and machine learning (ML).
Examples of topics pertinent to this call include, but are not limited to:
Duration: 3 years
Eligibility: Applications may be submitted by domestic (US) and foreign non-profit organizations and public and private entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and, where relevant, eligible agencies of the federal government.
Applicants must hold an MD, DMD, DVM, PhD, or equivalent degree, and hold a faculty position or equivalent at a college, university, medical school or other research facility. There are no citizenship requirements
How to Apply: Applicants should submit an LOI, [2 pages maximum] online via RMS360 to be considered for a full proposal request. The LOI template provided on the RMS360 website must be used to complete the application to be considered for a full proposal request.
Deadline:
Examples of topics pertinent to this call include, but are not limited to:
- Improving the function and/or survival of renewable sources of insulin-producing cells (e.g. stem cell-derived islets).
- Developing immune protection strategies to prevent rejection of transplanted cells that do not rely on chronic systemic immunosuppression.
- Establishing methods of predicting transplanted cell survival and function prior to decline in c-peptide levels or glycaemic control.
- Implications of a specific therapeutic approach (cell type and protection strategy, site of implantation) for efficacy, safety and patient selection.
Duration: 3 years
Eligibility: Applications may be submitted by domestic (US) and foreign non-profit organizations and public and private entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and, where relevant, eligible agencies of the federal government.
Applicants must hold an MD, DMD, DVM, PhD, or equivalent degree, and hold a faculty position or equivalent at a college, university, medical school or other research facility. There are no citizenship requirements
How to Apply: Applicants should submit an LOI, [2 pages maximum] online via RMS360 to be considered for a full proposal request. The LOI template provided on the RMS360 website must be used to complete the application to be considered for a full proposal request.
Deadline:
- Letter of Intent: 23 September 2024 (outcome notification: 8 October)
- Full proposal: 5 November 2024
- More information about the call is available here.
- The proposal should be submitted on the online portal RMS360.
- For any other questions, please contact the Research Office.
Practical information
- Informed public
- Free